Content about NextWave Pharmaceuticals

October 22, 2012

Pfizer is buying the maker of an attention deficit hyperactivity disorder drug for almost $700 million, Pfizer said Monday.

NEW YORK — Pfizer is buying the maker of an attention deficit hyperactivity disorder drug for almost $700 million, Pfizer said Monday.

The drug maker announced that it would buy privately owned NextWave Pharmaceuticals, which makes the extended-release ADHD drug Quillivant XR (methylphenidate hydrochloride), which the Food and Drug Administration approved last month. The drug is expected to appear in pharmacies in January 2013.

March 29, 2011

Tris Pharma on Tuesday announced its relaunch of the MyKidz Iron product line, which includes two supplement products and one prescription-only product.

MONMOUTH JUNCTION, N.J. — Tris Pharma on Tuesday announced its relaunch of the MyKidz Iron product line, which includes two supplement products and one prescription-only product.

MyKidz Iron was launched in 2007 by NextWave Pharmaceuticals. In August 2010, NextWave partnered with Tris on developing medicines focused on the central nervous system. As part of that partnership, all non-CNS over-the-counter products were acquired by Tris.